trending Market Intelligence /marketintelligence/en/news-insights/trending/Zdp5Mq2d6iNiETubMGrF0Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Chugai 9-month profit climbs 66.9% YOY; 2019 outlook raised

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Chugai 9-month profit climbs 66.9% YOY; 2019 outlook raised

Chugai Pharmaceutical Co. Ltd. said its earnings for the first nine months rose 66.9% year over year and raised its outlook for 2019.

The Tokyo-based Roche Holding AG unit reported net income attributable to shareholders of ¥117.39 billion, up from ¥70.34 billion in the year-ago period.

EPS for the nine months ended Sept. 30 rose 66.8% to ¥214.17 from ¥128.39 for the same period in 2018.

Revenue for the nine months grew 19.3% on an annual basis to ¥508.85 billion from ¥426.44 billion. Additionally, operating profit grew 64.3% year over year to ¥160.88 billion from ¥97.91 billion.

For full year 2019, the Japanese drugmaker now expects core EPS to be ¥302.00, an increase from the previous forecast of ¥198.00.

Chugai also anticipates full-year revenue to reach ¥680.00 billion, up from its earlier outlook of ¥592.50 billion.

As of Oct. 23, US$1 was equivalent to ¥108.64.